Skip to main content
Terug
Watch Compare

SAB Biotherapeutics, Inc.

Datakwaliteit: 100%
Ook genoteerd als SABSW Nasdaq
SABS
Nasdaq Manufacturing Chemicals
€ 3,83
▲ € 0,10 (2,55%)
Marktkapitalisatie: 268,80 M
Prijs
€ 3,83
Marktkapitalisatie
268,80 M
Dagbereik
€ 3,65 — € 3,86
52-Weeksbereik
€ 1,14 — € 6,60
Volume
181.875
Openen € 3,71
50D / 200D Gem.
€ 4,01
4,61% below
50D / 200D Gem.
€ 3,12
22,55% above

Quick Summary

Belangrijkste Punten

ROE of 14,99% — decent returns on equity
Negative free cash flow of -45,71 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
14,99%
Boven sectorgemiddelde (-53,41%)
ROIC-50,96%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio10,50
Interest Coverage-203,41

Waardering

PE (TTM)
20,25
Boven sectorgemiddelde (-1,48)
P/B Ratio1,63
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 20,3 -1,5
P/B 1,6 1,6
ROE % 15,0 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) 13,27 M
ROE 14,99% ROA 12,43%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45,71 M
ROIC -50,96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,50
Interest Coverage -203,41 Asset Turnover 0,00
Working Capital 102,48 M Tangible Book Value 165,07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 20,25 Forward P/E N/A
P/B Ratio 1,63 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -17,00%
Market Cap 268,80 M Enterprise Value 239,38 M
Per Share
EPS (Diluted TTM) -0,79 Revenue / Share 0,00
FCF / Share -0,65 OCF / Share -0,64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -344,35%
SBC-Adj. FCF -48,80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Revenue 0,0 1,32 M 2,24 M 23,90 M —
Net Income 13,27 M -34,11 M -42,19 M -18,74 M -8.996,0
EPS (Diluted) -0,79 -3,68 -7,64 — —
Gross Profit — — — — —
Operating Income -48,95 M -42,91 M -38,08 M -28,92 M —
EBITDA — — — — —
R&D Expenses 34,35 M 30,25 M 16,52 M 36,44 M —
SG&A Expenses — — — — —
D&A 2,99 M 4,71 M 3,65 M 3,17 M —
Interest Expense 240.664,0 318.401,0 315.284,0 301.584,0 —
Income Tax 0,0 0,0 0,0 25.629,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 172,81 M 44,20 M 83,94 M 50,90 M 322.205,0
Total Liabilities 21,32 M 18,23 M 26,64 M 19,85 M —
Shareholders' Equity 151,49 M 25,97 M 57,30 M 31,06 M 16.004,0
Total Debt — — — — —
Cash & Equivalents 10,50 M 8,90 M 56,57 M 15,05 M —
Current Assets 101,05 M 23,79 M 58,91 M 22,10 M 87.094,0
Current Liabilities 10,68 M 7,98 M 10,81 M 14,99 M 306.201,0